Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to -$15.1 million.

  • Assembly Biosciences' Cash from Operations rose 72.82% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.7 million, marking a year-over-year decrease of 34300.04%. This contributed to the annual value of -$51.1 million for FY2024, which is 32475.93% down from last year.
  • Per Assembly Biosciences' latest filing, its Cash from Operations stood at -$15.1 million for Q3 2025, which was up 72.82% from -$16.8 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Cash from Operations high stood at $73.6 million for Q4 2023, and its period low was -$33.3 million during Q1 2021.
  • In the last 5 years, Assembly Biosciences' Cash from Operations had a median value of -$18.4 million in 2024 and averaged -$13.8 million.
  • Per our database at Business Quant, Assembly Biosciences' Cash from Operations plummeted by 27736.24% in 2021 and then surged by 48250.23% in 2023.
  • Quarter analysis of 5 years shows Assembly Biosciences' Cash from Operations stood at -$19.4 million in 2021, then rose by 0.56% to -$19.3 million in 2022, then skyrocketed by 482.5% to $73.6 million in 2023, then crashed by 100.55% to -$407000.0 in 2024, then tumbled by 3618.18% to -$15.1 million in 2025.
  • Its last three reported values are -$15.1 million in Q3 2025, -$16.8 million for Q2 2025, and -$23.4 million during Q1 2025.